EP3446693 - PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS COMPRISING ALUMINIUM ACETATE FOR TOPICAL APPLICATION WITH ASTRINGENT AND ANTIMICROBIAL EFFECT [Right-click to bookmark this link] | |||
Former [2019/09] | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS FOR TOPICAL APPLICATION WITH ASTRINGENT AND ANTIMICROBIAL EFFECT | ||
[2020/24] | Status | No opposition filed within time limit Status updated on 17.09.2021 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 09.10.2020 | ||
Former | Grant of patent is intended Status updated on 27.05.2020 | ||
Former | Request for examination was made Status updated on 23.08.2019 | ||
Former | The application has been published Status updated on 25.01.2019 | Most recent event Tooltip | 03.05.2024 | Lapse of the patent in a contracting state New state(s): MK | published on 05.06.2024 [2024/23] | Applicant(s) | For all designated states Hiantis S.r.l. Via Sofonisba Anguissola, 2 20146 Milano / IT | [2019/09] | Inventor(s) | 01 /
ROMANO, Paolo Via Sofonisba Anguissola, 2 20146 Milano / IT | [2019/09] | Representative(s) | Ferreccio, Rinaldo Botti & Ferrari S.p.A. Via Cappellini, 11 20124 Milano / IT | [N/P] |
Former [2019/09] | Ferreccio, Rinaldo Botti & Ferrari S.r.l. Via Cappellini, 11 20124 Milano / IT | Application number, filing date | 18197035.1 | 15.02.2016 | [2019/09] | Priority number, date | IT2015MI00243 | 19.02.2015 Original published format: IT MI20150243 | [2019/09] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3446693 | Date: | 27.02.2019 | Language: | EN | [2019/09] | Type: | B1 Patent specification | No.: | EP3446693 | Date: | 11.11.2020 | Language: | EN | [2020/46] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 29.01.2019 | Classification | IPC: | A61K33/06, A61K31/185, A61K31/19, A61P17/00, A61P17/02, A61P17/04, A61K31/18, A61K33/32, A61K45/06 | [2019/09] | CPC: |
A61K31/19 (EP);
A61K31/18 (EP);
A61K31/185 (EP);
A61K33/06 (EP);
A61K33/32 (EP);
A61K45/06 (EP);
| C-Set: |
A61K31/185, A61K2300/00 (EP);
A61K31/18, A61K2300/00 (EP);
A61K31/19, A61K2300/00 (EP);
A61K33/06, A61K2300/00 (EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/39] |
Former [2019/09] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND FORMULIERUNGEN ENTHALTEND ALUMINIUMACETAT ZUR TOPISCHEN ANWENDUNG MIT ADSTRINGIERENDER UND ANTIMIKROBIELLER WIRKUNG | [2020/24] | English: | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS COMPRISING ALUMINIUM ACETATE FOR TOPICAL APPLICATION WITH ASTRINGENT AND ANTIMICROBIAL EFFECT | [2020/24] | French: | COMPOSITIONS PHARMACEUTIQUES ET FORMULATIONS COMPRENANT DE L ́ACÉTATE D'ALUMINIUM POUR APPLICATION TOPIQUE AVEC EFFET ASTRINGENT ET ANTIMICROBIEN | [2020/24] |
Former [2019/09] | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND FORMULIERUNGEN ZUR TOPISCHEN ANWENDUNG MIT ADSTRINGIERENDER UND ANTIMIKROBIELLER WIRKUNG | ||
Former [2019/09] | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS FOR TOPICAL APPLICATION WITH ASTRINGENT AND ANTIMICROBIAL EFFECT | ||
Former [2019/09] | COMPOSITIONS PHARMACEUTIQUES ET FORMULATIONS POUR APPLICATION TOPIQUE AVEC EFFET ASTRINGENT ET ANTIMICROBIEN | Examination procedure | 20.08.2019 | Amendment by applicant (claims and/or description) | 20.08.2019 | Examination requested [2019/39] | 20.08.2019 | Date on which the examining division has become responsible | 28.05.2020 | Communication of intention to grant the patent | 29.09.2020 | Fee for grant paid | 29.09.2020 | Fee for publishing/printing paid | 29.09.2020 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP16155637.8 / EP3058945 | Opposition(s) | 12.08.2021 | No opposition filed within time limit [2021/42] | Fees paid | Renewal fee | 27.09.2018 | Renewal fee patent year 03 | 20.02.2019 | Renewal fee patent year 04 | 20.02.2020 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 15.02.2016 | AL | 11.11.2020 | AT | 11.11.2020 | CY | 11.11.2020 | CZ | 11.11.2020 | DK | 11.11.2020 | EE | 11.11.2020 | FI | 11.11.2020 | HR | 11.11.2020 | IT | 11.11.2020 | LT | 11.11.2020 | LV | 11.11.2020 | MC | 11.11.2020 | MK | 11.11.2020 | NL | 11.11.2020 | PL | 11.11.2020 | RO | 11.11.2020 | RS | 11.11.2020 | SE | 11.11.2020 | SI | 11.11.2020 | SK | 11.11.2020 | SM | 11.11.2020 | BG | 11.02.2021 | NO | 11.02.2021 | GR | 12.02.2021 | IE | 15.02.2021 | LU | 15.02.2021 | BE | 28.02.2021 | CH | 28.02.2021 | LI | 28.02.2021 | IS | 11.03.2021 | PT | 11.03.2021 | [2024/23] |
Former [2023/33] | HU | 15.02.2016 | |
AL | 11.11.2020 | ||
AT | 11.11.2020 | ||
CY | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IE | 15.02.2021 | ||
LU | 15.02.2021 | ||
BE | 28.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2023/30] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CY | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IE | 15.02.2021 | ||
LU | 15.02.2021 | ||
BE | 28.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2022/34] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IE | 15.02.2021 | ||
LU | 15.02.2021 | ||
BE | 28.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2022/23] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IE | 15.02.2021 | ||
LU | 15.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2022/10] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IE | 15.02.2021 | ||
LU | 15.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
PT | 11.03.2021 | ||
Former [2022/07] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IE | 15.02.2021 | ||
LU | 15.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/50] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SI | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
LU | 15.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/48] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
IT | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
LU | 15.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/46] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
NL | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
LU | 15.02.2021 | ||
CH | 28.02.2021 | ||
LI | 28.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/45] | AL | 11.11.2020 | |
AT | 11.11.2020 | ||
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/41] | AT | 11.11.2020 | |
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
MC | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/37] | AT | 11.11.2020 | |
CZ | 11.11.2020 | ||
DK | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/36] | AT | 11.11.2020 | |
CZ | 11.11.2020 | ||
EE | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/35] | AT | 11.11.2020 | |
CZ | 11.11.2020 | ||
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RO | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SK | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/33] | AT | 11.11.2020 | |
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LT | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/32] | AT | 11.11.2020 | |
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
SM | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/28] | AT | 11.11.2020 | |
FI | 11.11.2020 | ||
HR | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/25] | AT | 11.11.2020 | |
FI | 11.11.2020 | ||
LV | 11.11.2020 | ||
PL | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
IS | 11.03.2021 | ||
PT | 11.03.2021 | ||
Former [2021/23] | AT | 11.11.2020 | |
FI | 11.11.2020 | ||
LV | 11.11.2020 | ||
RS | 11.11.2020 | ||
SE | 11.11.2020 | ||
BG | 11.02.2021 | ||
NO | 11.02.2021 | ||
GR | 12.02.2021 | ||
PT | 11.03.2021 | ||
Former [2021/22] | FI | 11.11.2020 | |
RS | 11.11.2020 | ||
NO | 11.02.2021 | ||
PT | 11.03.2021 | ||
Former [2021/21] | FI | 11.11.2020 | |
PT | 11.03.2021 | ||
Former [2021/20] | FI | 11.11.2020 | Documents cited: | Search | CN101474421 [ ]; | [A]US6656928 (MCCADDEN MICHAEL E [US]) [A] 1-5* abstract *; | [A]US2005191366 (MCCADDEN MICHAEL E [US]) [A] 1-5 * claims 1-3 *; | [A]CN101474421 (PEIRONG SONG [CN]) [A] 1-5 * abstract *; | [A]US7790771 (RAPP HORST [DE], et al) [A] 1-5 * abstract *; | [ ] - DATABASE WPI, 0, Derwent World Patents Index, vol. 2009, no. 54, Database accession no. 2009-L62420, XP002757036 & CN101474421 A 20090708 (SONG P) [ ] * abstract * | by applicant | US2824042 | - ALLEN, LOYD V., JR., Remington's Pharmaceutical Sciences | - THORP MA; GARDINER IB; PRESCOTT CA, "Burow's solution in the treatment of active mucosal chronic suppurative otitis media: determining an effective dilution", J Laryngol Otol., (20000600), vol. 114, no. 6, pages 432 - 6 | - THORP MA; OLIVER SP; KRUGER J; PRESCOTT CA, "Determination of the lowest dilution of aluminium acetate solution able to inhibit in vitro growth of organisms commonly found in chronic suppurative otitis media", J Laryngol Otol., (20001100), vol. 114, no. 11, pages 830 - 1 | - "Food and Drug Administration, HHS. Astringent drug products that produce aluminum acetate; skin protectant drug products for over-the-counter human use; technical amendment. Final rule; technical amendment", Fed Regist., (20090306), vol. 74, no. 43, pages 9759 - 65 | - HSIEH MH; YU CM; YU VL; CHOW JW, "Synergy assessed by checkerboard. A critical analysis", Diagn Microbiol Infect Dis., (19930500), vol. 16, no. 4, doi:doi:10.1016/0732-8893(93)90087-N, pages 343 - 9, XP023915582 DOI: http://dx.doi.org/10.1016/0732-8893(93)90087-N | - WHITE RL; BURGESS DS; MANDURU M; BOSSO JA, "Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test", Antimicrob Agents Chemother, (19960800), vol. 40, no. 8, pages 1914 - 8, XP055052950 | - CHEN YL; LEHMAN VN; AVERETTE AF; PERFECT JR; HEITMAN J, Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans | - PERRINS N; HOWELL SA; MOORE M; BOND R, "Inhibition of the growth in vitro of Trichophyton mentagrophytes, Trichophyton erinacei and Microsporum persicolor by miconazole and chlorhexidine", Vet Dermatol., (20051000), vol. 16, no. 5, pages 330 - 3 | - SOPIRALA MM; MANGINO JE; GEBREYES WA; BILLER B; BANNERMAN T; BALADA-LLASAT JM; PANCHOLI P, "Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii", Antimicrob Agents Chemother, (20101100), vol. 54, no. 11, doi:doi:10.1128/AAC.00497-10, pages 4678 - 83, XP055151857 DOI: http://dx.doi.org/10.1128/AAC.00497-10 | - DOVI JV; HE LK; DIPIETRO LA, "Accelerated wound closure in neutrophil-depleted mice", J Leukoc Biol., (20030400), vol. 73, no. 4, pages 448 - 55 |